度骨化醇
度骨化醇结构式
|
常用名 | 度骨化醇 | 英文名 | Doxercalciferol |
|---|---|---|---|---|
| CAS号 | 54573-75-0 | 分子量 | 412.648 | |
| 密度 | 1.0±0.1 g/cm3 | 沸点 | 538.7±50.0 °C at 760 mmHg | |
| 分子式 | C28H44O2 | 熔点 | 138-140ºC | |
| MSDS | 中文版 美版 | 闪点 | 224.0±24.7 °C | |
| 符号 |
GHS06 |
信号词 | Danger |
|
Calcium regulates FGF-23 expression in bone.
Endocrinology 154(12) , 4469-82, (2013) Calcium has recently been shown to regulate fibroblast growth factor 23 (FGF-23), a bone-derived phosphate and vitamin D-regulating hormone. To better understand the regulation of FGF-23 by calcium, phosphorus, 1,25 dihydroxyvitamin D3 [1,25(OH)2D], and PTH, ... |
|
|
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Clin. J. Am. Soc. Nephrol. 10(1) , 98-109, (2015) Elevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction of practice guidelines suggesting higher parathyroid hormone targets than those previously recommended, changes in parathyroid... |
|
|
A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.
Molecules 14(10) , 3869-80, (2009) Alfacalcidol (1alpha-hydroxyvitamin D(3)) has been widely used since 1981 as a prodrug for calcitriol (1alpha,25-dihydroxyvitamin D(3)) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalcifero... |
|
|
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
Clin. Cancer Res. 14(8) , 2437-43, (2008) Docetaxel is standard of care for androgen-independent prostate cancer (AIPC). Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat AIPC.Chemothera... |
|
|
Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
Blood Purif. 29(2) , 163-76, (2010) Calcium mass balance (Ca(MB)) is determined by the difference between Ca absorbed between dialyses (Ca(Abs)) and the Ca removed during dialysis (J(d)Ca(2+)). A mathematical model to quantify (1) Ca(Abs) as a function of Ca intake (Ca(INT)) and the doses of vi... |
|
|
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
Prostate 73(9) , 970-8, (2013) Prostate cancer is the most common malignancy and second leading cause of cancer related deaths in American men supporting the study of prostate cancer chemoprevention. Major risk factors for this disease have been associated with low serum levels of vitamin ... |
|
|
Doxercalciferol treatment of secondary hyperparathyroidism.
Ann. Pharmacother. 40(11) , 1955-65, (2006) To review the pharmacology, pharmacokinetics, effectiveness, safety, and therapeutic considerations related to the use of doxercalciferol in the treatment of secondary hyperparathyroidism.A MEDLINE search (1966-June 2006) was conducted using the key words vit... |
|
|
Doxercalciferol, a Pro-hormone of Vitamin D, Prevents the Development of Cardiac Hypertrophy in Rats
J. Card. Fail. 17(12) , 1051-8, (2011) Background Activated vitamin D analog, paricalcitol, has been shown to attenuate the development of cardiac hypertrophy in Dahl salt sensitive (DSS) rats. To determine whether an antihypertrophic effect is class specific, we tested if doxercalciferol (a pro-h... |
|
|
Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
Am. J. Nephrol. 29(2) , 71-8, (2009) National Kidney Foundation's Kidney Disease Outcome Quality Initiative (KDOQI) guidelines offer an outline for providing standardized care for best outcomes in chronic kidney disease (CKD). It is unknown whether real-world treatment practices follow these gui... |
|
|
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
Leuk. Lymphoma 49(1) , 57-61, (2008) We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5 microg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No... |